found that after nine breast cancer patients with tHER2−/cHER2+ received Herceptin-containing schedules, three achieved partial or complete response (16); in another study by Wang et al., tHER2- patients with a higher number of HER2+ CTC may get more benefit from the HER2-targeted therapy, who achieved a significantly improved progression-free survival (12). Here, ERBB2 is linked to breast carcinoma.